Continuous Monitoring of Left Atrial Pressure during MitraClip, Regardless Echocardiography

The aim of this study was to assess the use of measuring left atrial pressure to complement transesophageal echocardiography and doppler imaging.

MitraClip: ¿debemos intervenir antes a nuestros pacientes?Procedure efficacy is measured in the cath lab by echocardiography. However, these measurements are operator dependent and might be influenced by left ventricular function and changes in left atrial compliance.

 

The study looked at continuous left sided pressure in 50 patients undergoing MitraClip. These measurements included left atrial V-wave pressure, and left atrial mean, systolic, and end-diastolic pressures. Left atrial pressures were indexed to left ventricular pressures to compensate for variations in afterload during procedure.


Read also: TCT 2018 | TriValve: Mitraclip for the Tricuspid Valve.


70% of patients had degenerative mitral regurgitation. Mitral regurgitation grade by echocardiography decreased from 3+ to 0+, and atrial V-wave (p<0.001), mean left atrial pressure (p=0.007), end diastolic pressure (p=0.001) and all left atrial pressures indexed values also decreased after MitraClip.

 

Intra-procedural increase of mean left atrial pressure was associated to a smaller number of rehospitalizations for cardiac failure and more chances to reach functional class III or IV at follow-up. These events could not be predicted by post procedure 2+ mitral regurgitation.

 

Conclusions

This study shows the value of continued real-time monitoring of left atrial pressure to predict events after treating mitral regurgitation with MitraClip. An increase in left atrial mean pressure is a predictor of worse prognosis at short term, regardless echocardiographic findings.

 

Original title: Continuous Direct Left Atrial Pressure. Intraprocedural Measurement Predicts Clinical Response Following MitraClip Therapy.

Reference: Shingo Kuwata et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....